Breyanzi — Total Revenues
Bristol-Myers Squibb Breyanzi — Total Revenues increased by 4.4% to $359.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 60.3%, from $224.00M to $359.00M. Over 3 years (FY 2021 to FY 2024), Breyanzi — Total Revenues shows an upward trend with a 104.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and clinical adoption of the therapy, while a decrease may signal competitive pressure or manufacturing constraints inherent in complex cell therapies.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Breyanzi, a chimeric antigen r...
Peer comparison
Comparable to revenue metrics for specialized oncology or cell-therapy products at major biopharmaceutical peers, often evaluated based on launch trajectory and market share in hematology.
bmy_segment_breyanzi_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.00M | $30.00M | $40.00M | $44.00M | $39.00M | $44.00M | $55.00M | $71.00M | $100.00M | $92.00M | $101.00M | $107.00M | $153.00M | $224.00M | $263.00M | $263.00M | $344.00M | $359.00M |
| QoQ Change | — | +76.5% | +33.3% | +10.0% | -11.4% | +12.8% | +25.0% | +29.1% | +40.8% | -8.0% | +9.8% | +5.9% | +43.0% | +46.4% | +17.4% | +0.0% | +30.8% | +4.4% |
| YoY Change | — | — | — | — | +129.4% | +46.7% | +37.5% | +61.4% | +156.4% | +109.1% | +83.6% | +50.7% | +53.0% | +143.5% | +160.4% | +145.8% | +124.8% | +60.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's breyanzi — total revenues?
- Bristol-Myers Squibb (BMY) reported breyanzi — total revenues of $359.00M in Q3 2025.
- How has Bristol-Myers Squibb's breyanzi — total revenues changed year-over-year?
- Bristol-Myers Squibb's breyanzi — total revenues increased by 60.3% year-over-year, from $224.00M to $359.00M.
- What is the long-term trend for Bristol-Myers Squibb's breyanzi — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's breyanzi — total revenues has grown at a 104.8% compound annual growth rate (CAGR), from $87.00M to $747.00M.
- What does breyanzi — total revenues mean?
- Total revenue generated from the sales of the CAR T-cell therapy product Breyanzi.